UPDATE -- Savara to Present at Bank of America Merrill Lynch 2018 Healthcare Conference on May 15th
May 15 2018 - 12:26PM
Savara Inc. (NASDAQ:SVRA), an orphan lung disease company,
announced today that the Company's Chief Executive Officer, Rob
Neville, will present at the Bank of America Merrill Lynch 2018
Healthcare Conference on Tuesday May 15th, 2018 at 1:55 p.m.
Pacific Time at the Encore Hotel in Las Vegas.
Interested parties can access a live audio webcast on the Savara
website at www.savarapharma.com. An archived presentation will be
available on the website for 30 days.
About Savara Savara Inc. is an
orphan lung disease company. Savara's pipeline comprises:
Molgradex, an inhaled granulocyte-macrophage colony-stimulating
factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary
alveolar proteinosis, and in Phase 2a development for NTM lung
infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for
treatment of MRSA infection in cystic fibrosis. Savara's strategy
involves expanding its pipeline of potentially best-in-class
products through indication expansion, strategic development
partnerships and product acquisitions, with the goal of becoming a
leading company in its field. Savara's management team has
significant experience in orphan drug development and pulmonary
medicine, identifying unmet needs, developing and acquiring new
product candidates, and effectively advancing them to approvals and
commercialization. More information can be found at
www.savarapharma.com. (Twitter: @SavaraPharma)
Savara may announce material information about
its finances, product candidates, clinical trials and other matters
to its investors using its investor relations website
(http://savarapharma.com/investors), SEC filings, press releases,
public conference calls and webcasts. Savara uses these
channels, as well as social media, to communicate with its
stockholders and the public about the company and other issues. It
is possible that the information Savara posts on its website and
social media could be deemed to be material information. Therefore,
Savara encourages investors, the media, and others interested in
the company to review the information Savara posts on its investor
relations website (referenced above) and any social media channels
listed on its website from time to time.
Contacts:
Savara: Ioana C. Hone (ir@savarapharma.com) (512) 961-1891
For IR: Solebury Trout Gitanjali Jain Ogawa
(Gogawa@troutgroup.com) (646) 378-2949
For Media: Neon InteractivePatrick Wallace
(patrick@neoninteractive.com) (619) 200-7856
Savara (NASDAQ:SVRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Savara (NASDAQ:SVRA)
Historical Stock Chart
From Apr 2023 to Apr 2024